A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (vol 24, 876, 2024)


Por: Leary, A, Estévez-García, P, Sabatier, R, Ray-Coquard, I, Romeo, M, Barretina-Ginesta, P, Gil-Martin, M, Garralda, E, Bosch-Barrera, J, Morán, T, Martin-Martorell, P, Nadal, E, Gascón, P, Rodon, J, Lizcano, JM, Muñoz-Guardiola, P, Fierro-Durán, G, Pedrós-Gámez, O, Pérez-Montoyo, H, Yeste-Velasco, M, Cortal, M, Pérez-Campos, A, Alfon, J, Domenech, C, Pérez-Fidalgo, A and Oaknin, A

Publicada: 29 jul 2024
Resumen:


Filiaciones:
Leary, A:
 Inst Gustave Roussy, Med Oncol, Villejuif, France

Estévez-García, P:
 Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain

Sabatier, R:
 Aix Marseille Univ, Inst Paoli Calmettes, Dept Med Oncol, Inserm,CNRS, 232 Blvd Sainte Marguer, Marseille, France

Ray-Coquard, I:
 Ctr Leon Berard, Med Oncol, Lyon, France

:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Germans Trias & Pujol Inst, Badalona Appl Res Grp Oncol,Dept Med Oncol,Dept Me, Badalona, Spain

Barretina-Ginesta, P:
 Univ Girona UdG, Girona Biomed Res Inst IDIBGI, Med Sch, Precis Oncol Grp OncoGIR Pro,Med Oncol Dept, Girona, Spain

 Univ Girona UdG, Inst Catala Oncol ICO, Med Sch, Dept Med Sci, Girona, Spain

Gil-Martin, M:
 Catalan Inst Oncol, Med Oncol, Barcelona, Spain

 IDIBELL, Barcelona, Spain

Garralda, E:
 Vall dHebron Inst Oncol VHIO, Med Oncol Serv, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

Bosch-Barrera, J:
 Univ Girona UdG, Girona Biomed Res Inst IDIBGI, Med Sch, Precis Oncol Grp OncoGIR Pro,Med Oncol Dept, Girona, Spain

 Univ Girona UdG, Inst Catala Oncol ICO, Med Sch, Dept Med Sci, Girona, Spain

Morán, T:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Germans Trias & Pujol Inst, Badalona Appl Res Grp Oncol,Dept Med Oncol,Dept Me, Badalona, Spain

Martin-Martorell, P:
 Hosp Clin Univ, Med Oncol, INCLIVA, Valencia, Spain

Nadal, E:
 Catalan Inst Oncol, Med Oncol, Barcelona, Spain

 IDIBELL, Barcelona, Spain

Gascón, P:
 Univ Barcelona, Hosp Clin, Med Oncol Serv, Barcelona, Spain

Rodon, J:
 Univ Texas MD Anderson Canc Ctr, Early Drug Dev, Houston, TX USA

Lizcano, JM:
 Univ Autonoma Barcelona, Inst Neurociencias, Dept Biochem & Mol Biol, Barcelona, Spain

 Vall Hebron Inst Recerca VHIR, Prot Kinases Canc Res, Barcelona, Spain

Muñoz-Guardiola, P:
 Univ Autonoma Barcelona, Inst Neurociencias, Dept Biochem & Mol Biol, Barcelona, Spain

 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Fierro-Durán, G:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Pedrós-Gámez, O:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Pérez-Montoyo, H:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Yeste-Velasco, M:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Cortal, M:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Pérez-Campos, A:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Alfon, J:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Domenech, C:
 Abil Pharmaceut, Res & Dev, Barcelona, Spain

Pérez-Fidalgo, A:
 Hosp Clin Univ, Med Oncol, INCLIVA, Valencia, Spain

Oaknin, A:
 Vall dHebron Inst Oncol VHIO, Med Oncol Serv, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
ISSN: 14712407





BMC Cancer
Editorial
BioMed Central, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Correction
Volumen: 24 Número: 1
Páginas:
WOS Id: 001280498800003
ID de PubMed: 39075404
imagen Green Submitted, gold

MÉTRICAS